Q3 25 EPS
$2.38
Q3 25 Revenue
$15.19B
vs S&P Since Q3 25
+4.9%
BEATING MARKET
AZN +12.3% vs S&P +7.4%
Market Reaction
Did AZN Beat Earnings? Q3 2025 Results
AstraZeneca delivered a solid Q3 2025, with revenue climbing 2.0% year-over-year to $15.19 billion and core EPS rising to $2.38, as the pharmaceutical giant's oncology franchise continued to carry significant weight across the portfolio. The quarter'… Read more AstraZeneca delivered a solid Q3 2025, with revenue climbing 2.0% year-over-year to $15.19 billion and core EPS rising to $2.38, as the pharmaceutical giant's oncology franchise continued to carry significant weight across the portfolio. The quarter's clearest growth engine was Oncology, which generated $6.64 billion, or 44% of total revenue, anchored by Tagrisso at $1.86 billion and propelled by standout performances from Imfinzi, up 33% to $1.60 billion on new bladder and lung cancer indications, and Enhertu, which surged 40% to $714 million on accelerating HER2-low breast cancer uptake. The pipeline momentum was equally notable, with 16 positive Phase III readouts in the first nine months, reinforcing the company's long-running ambition to launch 20 new medicines and reach $80 billion in revenue by 2030. Looking ahead, AstraZeneca reiterated its full-year 2025 guidance for high single-digit total revenue growth and low double-digit core EPS growth at constant exchange rates, while announcing a planned dividend increase to $3.20 per share for the year.
Key Takeaways
- • Oncology revenue growth of 19% YoY in Q3 led by Imfinzi (+33%), Enhertu (+40%), and Truqap (+55%)
- • R&I revenue growth of 15% YoY driven by Tezspire (+50%), Saphnelo (+45%), and Breztri (+21%)
- • Strong demand growth across all major geographic regions
- • New launch indications in bladder cancer and lung cancer for Imfinzi
- • Rapid adoption of Enhertu in HER2-low and ultralow breast cancer
- • Farxiga growth driven by heart failure and chronic kidney disease indications
AZN YoY Financials
Q3 2025 vs Q3 2024, source: SEC Filings
AZN Revenue by Segment
With YoY comparisons, source: SEC Filings
AZN Revenue by Geography
With YoY comparisons, source: SEC Filings
“The strong underlying momentum across our business through the first nine months of the year sets us up well to sustain growth through 2026 and has us on track to deliver our 2030 ambition.”
— Pascal Soriot, Q3 2025 Earnings Press Release
AZN Earnings Trends
AZN vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
AZN EPS Trend
Earnings per share: estimate vs actual
AZN Revenue Trend
Quarterly revenue: estimate vs actual
AZN Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 | — | $2.58 | — | $15.29B | — |
| Q4 25 FY | — | $2.12 | — | $15.50B | +1.26% |
| FY Full Year | $4.59 | $9.16 | +99.72% | $58.74B | +0.33% |
| Q3 25 FY | — | $2.38 | — | $15.19B | — |
| FY Full Year | $4.59 | — | — | — | — |
| Q1 25 | — | $2.49 | — | $13.59B | — |
| Q4 24 FY | — | $2.09 | — | $14.89B | — |
| FY Full Year | — | $8.21 | — | $54.07B | — |